Iovance

Philadelphia, US · 1 known investors

Iovance develops T-cell-based immunotherapies, including tumor-infiltrating lymphocyte (TIL) therapies and genetically modified TIL therapies, designed to target neoantigens unique to each patient's tumor. The company focuses on treating advanced solid tumor cancers and manufactures its therapies at its Cell Therapy Center in Philadelphia.